$ADPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Adaptive Biotechnologies Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Adaptive Biotechnologies Corp. Get notifications about new insider transactions in Adaptive Biotechnologies Corp for free.
Page: < prev 1 2 3 4 5 6 7 ... 11 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 59.20 | 5,280 | 312,576 | 2,010 | 7.3 K to 2 K (-72.43 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 58.58 | 7,710 | 451,652 | 7,290 | 15 K to 7.3 K (-51.40 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Buy | M | 6.32 | 15,000 | 94,800 | 15,000 | 0 to 15 K |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 56.01 | 4,055 | 227,121 | 0 | 4.1 K to 0 (-100.00 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 55.36 | 10,945 | 605,915 | 4,055 | 15 K to 4.1 K (-72.97 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Buy | M | 6.32 | 15,000 | 94,800 | 15,000 | 0 to 15 K |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 7,790 | 49,233 | 194,750 | |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 7,790 | 49,233 | 202,540 | |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 60.57 | 2,379 | 144,096 | 679 | 3.1 K to 679 (-77.80 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 59.80 | 2,501 | 149,560 | 3,058 | 5.6 K to 3.1 K (-44.99 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 58.76 | 2,910 | 170,992 | 5,559 | 8.5 K to 5.6 K (-34.36 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 7,790 | 49,233 | 8,469 | 679 to 8.5 K (+1,147.28 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 56.18 | 3,590 | 201,686 | 679 | 4.3 K to 679 (-84.09 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 55.54 | 4,200 | 233,268 | 4,269 | 8.5 K to 4.3 K (-49.59 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 7,790 | 49,233 | 8,469 | 679 to 8.5 K (+1,147.28 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 7.27 | 1,562 | 11,356 | 35,938 | |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 2,604 | 17,056 | 52,084 | |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 2,604 | 17,056 | 23,438 | |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 56.41 | 300 | 16,923 | 0 | 300 to 0 (-100.00 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 55.61 | 6,470 | 359,797 | 300 | 6.8 K to 300 (-95.57 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 7.27 | 1,562 | 11,356 | 6,770 | 5.2 K to 6.8 K (+29.99 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 2,604 | 17,056 | 5,208 | 2.6 K to 5.2 K (+100.00 %) |
| Feb 03 2021 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 2,604 | 17,056 | 2,604 | 0 to 2.6 K |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 6.55 | 1,771 | 11,600 | 24,792 | |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 7.80 | 1,042 | 8,128 | 28,125 | |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 57.76 | 628 | 36,273 | 1,300 | 1.9 K to 1.3 K (-32.57 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 56.59 | 1,090 | 61,683 | 1,928 | 3 K to 1.9 K (-36.12 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 55.71 | 1,095 | 61,002 | 3,018 | 4.1 K to 3 K (-26.62 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 6.55 | 1,771 | 11,600 | 4,113 | 2.3 K to 4.1 K (+75.62 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 7.80 | 1,042 | 8,128 | 2,342 | 1.3 K to 2.3 K (+80.15 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | M | 6.32 | 15,000 | 94,800 | 95,000 | |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 57.74 | 1,796 | 103,701 | 0 | 1.8 K to 0 (-100.00 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 56.60 | 4,910 | 277,906 | 1,796 | 6.7 K to 1.8 K (-73.22 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 55.77 | 8,294 | 462,556 | 6,706 | 15 K to 6.7 K (-55.29 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Buy | M | 6.32 | 15,000 | 94,800 | 15,000 | 0 to 15 K |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 50,000 | 316,000 | 65,000 | |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 50,000 | 316,000 | 115,000 | |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 57.70 | 2,184 | 126,017 | 1,000 | 3.2 K to 1,000 (-68.59 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 56.68 | 9,704 | 550,023 | 3,184 | 12.9 K to 3.2 K (-75.29 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 55.77 | 38,112 | 2,125,506 | 12,888 | 51 K to 12.9 K (-74.73 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 50,000 | 316,000 | 51,000 | 1,000 to 51 K (+5,000.00 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 57.00 | 18,523 | 1,055,811 | 1,000 | 19.5 K to 1,000 (-94.88 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 56.00 | 23,698 | 1,327,088 | 19,523 | 43.2 K to 19.5 K (-54.83 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 55.04 | 7,779 | 428,156 | 43,221 | 51 K to 43.2 K (-15.25 %) |
| Feb 01 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 50,000 | 316,000 | 51,000 | 1,000 to 51 K (+5,000.00 %) |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | M | 6.32 | 15,000 | 94,800 | 110,000 | |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | M | 6.32 | 15,000 | 94,800 | 125,000 | |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 56.68 | 2,147 | 121,692 | 0 | 2.1 K to 0 (-100.00 %) |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 55.96 | 9,420 | 527,143 | 2,147 | 11.6 K to 2.1 K (-81.44 %) |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 54.96 | 3,433 | 188,678 | 10,567 | 14 K to 10.6 K (-24.52 %) |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Buy | M | 6.32 | 15,000 | 94,800 | 15,000 | 0 to 15 K |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 59.99 | 1,700 | 101,983 | 0 | 1.7 K to 0 (-100.00 %) |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 59.37 | 6,913 | 410,425 | 1,700 | 8.6 K to 1.7 K (-80.26 %) |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 58.19 | 6,387 | 371,660 | 8,613 | 15 K to 8.6 K (-42.58 %) |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Buy | M | 6.32 | 15,000 | 94,800 | 15,000 | 0 to 15 K |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Option Exercise | M | 7.80 | 40,000 | 312,000 | 341,250 | |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Sell | S | 60.01 | 8,268 | 496,163 | 0 | 8.3 K to 0 (-100.00 %) |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Sell | S | 59.24 | 14,233 | 843,163 | 8,268 | 22.5 K to 8.3 K (-63.25 %) |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Sell | S | 58.22 | 17,499 | 1,018,792 | 22,501 | 40 K to 22.5 K (-43.75 %) |
| Jan 29 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Buy | M | 7.80 | 40,000 | 312,000 | 40,000 | 0 to 40 K |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 57.83 | 2,300 | 133,009 | 1,739,780 | 1.7 M to 1.7 M (-0.13 %) |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 57.32 | 4,300 | 246,476 | 1,742,080 | 1.7 M to 1.7 M (-0.25 %) |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 55.94 | 2,800 | 156,632 | 1,746,380 | 1.7 M to 1.7 M (-0.16 %) |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 55.01 | 600 | 33,006 | 1,749,180 | 1.7 M to 1.7 M (-0.03 %) |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 59.72 | 1,875 | 111,975 | 1,749,780 | 1.8 M to 1.7 M (-0.11 %) |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 58.79 | 3,246 | 190,832 | 1,751,655 | 1.8 M to 1.8 M (-0.18 %) |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 57.71 | 2,000 | 115,420 | 1,754,901 | 1.8 M to 1.8 M (-0.11 %) |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 56.26 | 1,000 | 56,260 | 1,756,901 | 1.8 M to 1.8 M (-0.06 %) |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 54.63 | 1,879 | 102,650 | 1,757,901 | 1.8 M to 1.8 M (-0.11 %) |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 65.23 | 100 | 6,523 | 1,759,780 | 1.8 M to 1.8 M (-0.01 %) |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 64.52 | 3,526 | 227,498 | 1,759,880 | 1.8 M to 1.8 M (-0.20 %) |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 63.63 | 2,524 | 160,602 | 1,763,406 | 1.8 M to 1.8 M (-0.14 %) |
| Jan 28 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 62.51 | 3,850 | 240,664 | 1,765,930 | 1.8 M to 1.8 M (-0.22 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 50,000 | 316,000 | 165,000 | |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 50,000 | 316,000 | 215,000 | |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 65.47 | 5,920 | 387,582 | 1,000 | 6.9 K to 1,000 (-85.55 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 64.54 | 20,785 | 1,341,464 | 6,920 | 27.7 K to 6.9 K (-75.02 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 63.65 | 12,977 | 825,986 | 27,705 | 40.7 K to 27.7 K (-31.90 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 62.71 | 10,318 | 647,042 | 40,682 | 51 K to 40.7 K (-20.23 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 50,000 | 316,000 | 51,000 | 1,000 to 51 K (+5,000.00 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 67.68 | 1,000 | 67,680 | 1,000 | 2 K to 1,000 (-50.00 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 67.03 | 17,436 | 1,168,735 | 2,000 | 19.4 K to 2 K (-89.71 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 65.69 | 20,953 | 1,376,403 | 19,436 | 40.4 K to 19.4 K (-51.88 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 65.08 | 10,611 | 690,564 | 40,389 | 51 K to 40.4 K (-20.81 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 50,000 | 316,000 | 51,000 | 1,000 to 51 K (+5,000.00 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | M | 6.32 | 15,000 | 94,800 | 140,000 | |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | M | 6.32 | 15,000 | 94,800 | 155,000 | |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 65.90 | 600 | 39,540 | 0 | 600 to 0 (-100.00 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 65.28 | 3,470 | 226,522 | 600 | 4.1 K to 600 (-85.26 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 64.32 | 10,930 | 703,018 | 4,070 | 15 K to 4.1 K (-72.87 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Buy | M | 6.32 | 15,000 | 94,800 | 15,000 | 0 to 15 K |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 67.79 | 500 | 33,895 | 0 | 500 to 0 (-100.00 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 67.05 | 8,816 | 591,113 | 500 | 9.3 K to 500 (-94.63 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 65.89 | 1,813 | 119,459 | 9,316 | 11.1 K to 9.3 K (-16.29 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 65.09 | 3,871 | 251,963 | 11,129 | 15 K to 11.1 K (-25.81 %) |
| Jan 27 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Buy | M | 6.32 | 15,000 | 94,800 | 15,000 | 0 to 15 K |
| Jan 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 23,370 | 147,698 | 210,330 | |
| Jan 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 67.59 | 2,100 | 141,939 | 679 | 2.8 K to 679 (-75.57 %) |
| Jan 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 66.90 | 17,329 | 1,159,310 | 2,779 | 20.1 K to 2.8 K (-86.18 %) |
| Jan 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 66.06 | 3,941 | 260,342 | 20,108 | 24 K to 20.1 K (-16.39 %) |
| Jan 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 23,370 | 147,698 | 24,049 | 679 to 24 K (+3,441.83 %) |
| Jan 25 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | M | 6.32 | 15,000 | 94,800 | 170,000 | |
| Jan 25 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 67.19 | 9,476 | 636,692 | 0 | 9.5 K to 0 (-100.00 %) |
| Jan 25 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 66.23 | 5,524 | 365,855 | 9,476 | 15 K to 9.5 K (-36.83 %) |
| Jan 25 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Buy | M | 6.32 | 15,000 | 94,800 | 15,000 | 0 to 15 K |
| Jan 22 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | M | 6.32 | 15,000 | 94,800 | 185,000 | |
| Jan 22 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 67.63 | 45 | 3,043 | 0 | 45 to 0 (-100.00 %) |
| Jan 22 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 66.87 | 8,511 | 569,131 | 45 | 8.6 K to 45 (-99.47 %) |
| Jan 22 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 66.15 | 6,444 | 426,271 | 8,556 | 15 K to 8.6 K (-42.96 %) |
| Jan 22 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Buy | M | 6.32 | 15,000 | 94,800 | 15,000 | 0 to 15 K |
| Jan 22 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 50,000 | 316,000 | 265,000 | |
| Jan 22 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 68.33 | 5,012 | 342,470 | 1,000 | 6 K to 1,000 (-83.37 %) |
| Jan 22 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 67.35 | 33,938 | 2,285,724 | 6,012 | 40 K to 6 K (-84.95 %) |
| Jan 22 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 66.82 | 11,050 | 738,361 | 39,950 | 51 K to 40 K (-21.67 %) |
| Jan 22 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 50,000 | 316,000 | 51,000 | 1,000 to 51 K (+5,000.00 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 71.14 | 100 | 7,114 | 1,769,780 | 1.8 M to 1.8 M (-0.01 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 70.42 | 8,300 | 584,486 | 1,769,880 | 1.8 M to 1.8 M (-0.47 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 50,000 | 316,000 | 315,000 | |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 70.66 | 6,889 | 486,777 | 1,000 | 7.9 K to 1,000 (-87.32 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 69.74 | 14,201 | 990,378 | 7,889 | 22.1 K to 7.9 K (-64.29 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 69.00 | 6,695 | 461,955 | 22,090 | 28.8 K to 22.1 K (-23.26 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 67.75 | 4,581 | 310,363 | 28,785 | 33.4 K to 28.8 K (-13.73 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 66.97 | 17,634 | 1,180,949 | 33,366 | 51 K to 33.4 K (-34.58 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 50,000 | 316,000 | 51,000 | 1,000 to 51 K (+5,000.00 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 50,000 | 316,000 | 133,700 | |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 50,000 | 316,000 | 183,700 | |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 68.20 | 4,661 | 317,880 | 679 | 5.3 K to 679 (-87.28 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 67.39 | 24,945 | 1,681,044 | 5,340 | 30.3 K to 5.3 K (-82.37 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 66.84 | 20,394 | 1,363,135 | 30,285 | 50.7 K to 30.3 K (-40.24 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 50,000 | 316,000 | 50,679 | 679 to 50.7 K (+7,363.77 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 70.75 | 2,100 | 148,575 | 679 | 2.8 K to 679 (-75.57 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 69.97 | 8,052 | 563,398 | 2,779 | 10.8 K to 2.8 K (-74.34 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 69.26 | 5,701 | 394,851 | 10,831 | 16.5 K to 10.8 K (-34.48 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 67.74 | 3,001 | 203,288 | 16,532 | 19.5 K to 16.5 K (-15.36 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 67.02 | 31,146 | 2,087,405 | 19,533 | 50.7 K to 19.5 K (-61.46 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 50,000 | 316,000 | 50,679 | 679 to 50.7 K (+7,363.77 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | M | 6.32 | 15,000 | 94,800 | 200,000 | |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | M | 6.32 | 15,000 | 94,800 | 215,000 | |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 68.34 | 6,370 | 435,326 | 0 | 6.4 K to 0 (-100.00 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 67.58 | 4,264 | 288,161 | 6,370 | 10.6 K to 6.4 K (-40.10 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 66.49 | 4,366 | 290,295 | 10,634 | 15 K to 10.6 K (-29.11 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Buy | M | 6.32 | 15,000 | 94,800 | 15,000 | 0 to 15 K |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 71.23 | 200 | 14,246 | 0 | 200 to 0 (-100.00 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 70.51 | 4,822 | 339,999 | 200 | 5 K to 200 (-96.02 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 69.54 | 7,415 | 515,639 | 5,022 | 12.4 K to 5 K (-59.62 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 68.72 | 2,563 | 176,129 | 12,437 | 15 K to 12.4 K (-17.09 %) |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Buy | M | 6.32 | 15,000 | 94,800 | 15,000 | 0 to 15 K |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | HILL NANCY LOUISE | EVP, Operations & P ... | Option Exercise | M | 4.07 | 23,000 | 93,610 | 27,000 | |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | HILL NANCY LOUISE | EVP, Operations & P ... | Option Exercise | M | 0.84 | 2,000 | 1,680 | 0 | |
| Jan 21 2021 | ADPT | Adaptive Biotechno ... | HILL NANCY LOUISE | EVP, Operations & P ... | Sell | S | 69.00 | 25,000 | 1,725,000 | 10,000 | 35 K to 10 K (-71.43 %) |